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SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-
PAMAM DENDRIMER BIOCONJUGATES  
 
By Gunjan Saxena 
 
 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biomedical Engineering at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2012 
 
Director: Hu Yang, Ph.D., Associate Professor, Biomedical Engineering 
 
 
A tumor targeted dendrimer based drug delivery system was designed and synthesized to 
carry chemotherapy drug doxorubicin. Polyamidoamine (PAMAM) dendrimer G4.5 was chosen 
as the underlying carrier. Anionic G4.5 is a good option for drug delivery as it consists of 128 
surface groups, is less cytotoxic and favorably biodistributed. The delivery system was 
synthesized using a layer-by layer arrangement of three functional entities: chemotherapy drug 
doxorubicin, monoclonal antibody Cetuximab against EGF receptor, and polyethylene glycol 
(PEG). Doxorubicin was attached via an acid-sensitive hydrazon linkage to the dendrimer. 
Macromolecules are taken in by cells through endocytosis. pH inside the early endosomes to 
lysosomes ranges from pH 6 to 4.5. These acidic conditions are favorable for release of drug 
bound to the dendrimer vehicle through acid-sensitive linkage. 35% of all solid tumors of brain 
express exceptionally high EGF receptors whereas normal brain tumors express less EGFR. This 
makes the EGFR a potent targeting moiety for targeted drug delivery. Cetuximab will serve as a 
targeting ligand to help the delivery system target tumor cells. PEG was incorporated as a linker 
xii 
 
between Cetuximab and dendrimer to avoid reticuloendothelial system (RES) uptake of the 
system, increase biocompatibility, increase drug half-life and other shortcomings associated with 
nanomaterials. Nuclear magnetic resonance spectroscopy (NMR), fluorescence anisotropy, and 
western blotting were used to confirm the conjugation of PEG, doxorubicin and cetuximab to the 
dendrimer. The synthesized delivery system was characterized using ultraviolet-visible 
spectroscopy (UV-Vis) to approximate the number of doxorubicin attached. Dynamic light 
scattering (DLS) and zeta potential were used to analyze the change in size and surface 
properties of dendrimer during the synthesis. Doxorubicin release studies were conducted at 
different pHs. Maximum doxorubicin was released at pH 4.5 indicating the successful acid-
sensitive linkage between the drug and dendrimer. Cytotoxicity studies indicated that the 
addition of PEG increased the biocompatibility as compared to free doxorubicin whereas; 
combination of doxorubicin and cetuximab exerted a significant toxic effect over a period of 72 
hours. The cellular uptake of the delivery system was higher than that of free doxorubicin. Free 
DOX localized mainly in the nucleus whereas, CTX-G4.5-PEG-DOX conjugate localized within 
both cytoplasm and nucleus after 6 hour incubation. The synthesized delivery system represents 
a potential targeted drug delivery system. 
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CHAPTER 1 INTRODUCTION 
According to the World Health Organization (WHO), brain diseases such as epilepsy, 
Alzheimer’s disease, cerebrovascular disease, brain cancers are a major healthcare problem 
worldwide. Particularly, brain cancer is one of the most complex and deadly diseases known to 
human beings. According to the Central Brain Tumor Registry of The United States, over 
612,000 people are living with primary brain and central nervous system (CNS) tumor being 
diagnosed. It was estimated that 64,530 new patients would be diagnosed with primary non-
malignant and malignant brain tumor in the US alone in 2011 (http://cbtrus.org/factsheet/fact 
sheet.html, cited December 3, 2011). 
The major factor limiting therapeutic treatment of CNS diseases is the brain’s effective 
protective mechanism known as the blood-brain barrier (BBB) (Pardridge et al., 2005). With the 
presence of BBB, only 2% of small-molecular-weight drugs pass through, whereas nearly all 
large-molecular-weight neurotherapeutics are excluded from the brain (Pardridge et al., 2005). 
Thus the treatment efficacy is largely dependent on drug delivery efficiency. Brain drug delivery 
routes such as trans-cranial drug delivery, trans-nasal brain drug delivery, and BBB disruption 
are invasive, potentially leading to irreversible side effects or allow a very limited distribution of 
drug in the brain. Some notable examples are implanting drug eluting wafers after surgical tumor 
removal, insertion of catheters for pumping drugs into the brain (Abbott et al., 2004; Pardridge et 
al., 2007). Some relatively less invasive delivery systems have been developed to utilize 
receptor- targeted delivery mechanism for enhanced brain drug uptake (Yan et al., 2011). In this 
approach, drug carriers, particularly nanocarriers, play an important role. Nanocarriers are 
unique as they are small in size. They help increase the permeability, half-life, solubility and 
stability of the drug in the body. Being the most versatile nanoscale building blocks, dendrimers 
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have received considerable attention. Among them polyamidoamine (PAMAM) dendrimers are 
most investigated (Yan et al., 2011; Yang et al., 2010; Lee et al., 2005). As opposed to linear 
polymers, dendrimers have highly branched, well-defined architecture with very low 
polydispersity (PDI) (Svenson et al., 2009). Furthermore, availability of a number of functional 
groups on their periphery can be used for attachment of drugs
 
(Kolhe et al., 2006; Kurtoglu et al., 
2009; Kono et al., 2008), solubilizing groups
 
(Gillies et al., 2005), targeting ligands
 
(Chandrasekar et al., 2007), or imaging agents
 
(Patri et al., 2004) for efficient drug delivery or 
imaging. 
In this thesis research, we designed and developed a brain-targeted PEGylated dendrimer 
drug delivery system for anticancer drug delivery. Biocompatible polyethylene glycol (PEG) was 
incorporated into the system aiming at reducing immunogenicity, minimizing particle 
aggregation, improving the carrier’s water solubility, decreasing reticuloendothelial system 
(RES) opsonization, and strengthening the enhanced permeability and retention (EPR) effect 
(Boswell et al., 2008). Doxorubicin (DOX), an anti-cancer drug, was used as a model drug. 
Chimeric monoclonal antibody Cetuximab (CTX) was used as a targeting ligand. It is a 150kDa 
IgG1K, produced by Sp2/0 mammalian cell line, against the epidermal growth factor receptor 
(EGFR) and its mutant form EGFRvIII over-expressed in 35% of all solid tumors
 
(Lahlou et al., 
2009). The synthesis involved step-by-step assembly of functional groups in sequence including 
PEG, DOX, CTX on the surface of PAMAM dendrimer G4.5. Particularly DOX was attached to 
the dendrimer via an acid-labile hydrazone linkage.  CTX-PEG-G4.5-DOX bioconjugates and 
intermediates were characterized using 
1
H-NMR, fluorescence anisotropy, western blotting, 
dynamic light scattering and zeta potential. The cellular uptake and cytotoxicity of the delivery 
system was investigated. The in vitro release kinetics of doxorubicin was also studied.  
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CHAPTER 2 BACKGROUND 
2.1 Blood brain barrier (BBB) 
The brain is a delicate organ, and evolution built very efficient ways to protect it. The 
physiological mechanism that alters the permeability of brain capillaries so as to maintain 
homeostasis of the brain is collectively referred to as the “blood-brain barrier.” A journey to 
understanding of BBB started a century ago. A German bacteriologist, Paul Ehrlich studied 
staining of brain in 1885. He observed that dyes did not have a staining affinity to the brain 
because intravenously administered aniline dyes stained every organ but the brain
 
(Wells et al., 
2005). In 1913, his student Edwin Goldman experimentally proved that dye could stain brain 
tissue but did not reach the brain. Furthermore, he found that dye injected through subarachnoid 
space stained cerebrospinal fluid (CSF) but not peripheral tissues. This demonstrated the 
existence of the ‘barrier.’ It was not until 1967 and introduction of high resolution microscopy 
that Resse and Karnovsky revealed that endothelial cells in mouse cerebral capillaries formed a 
structural barrier to horseradish peroxidase (HRP) (Reese and Karnovsky et al., 1967). Thus the 
statement that the BBB is “an endothelial barrier present in capillaries that course through the 
brain” was made (Rubin et al., 1999). 
Although the BBB is an important mechanism to protect the brain, it also represents a 
formidable barrier to therapeutics required for treatment of CNS diseases (Abbott et al., 1996). 
Nearly 100% large-molecular-weight pharmaceutics such as proteins, peptides, RNA 
interference (RNAi)-based drugs have limited transport across the BBB. Only small lipophilic 
molecules with molecular weight around or under 400-500 daltons can cross the BBB (Pardridge 
et al., 2007). But, these small molecules can only be effective in treating certain CNS diseases 
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such as chronic pain, epilepsy and insomnia (Pardridge et al., 2007). The presence of P-
glycoprotein on the luminal side of the BBB expels a variety of substances out of the brain to 
maintain homeostasis, making drug delivery to the brain even more challenging (Pardridge et al., 
1997; Golden et al., 1999; El Hafny et al., 1997). Transporter proteins or receptors present on the 
BBB help essential nutrients such as glucose, amino acids and transferrin to get into the brain 
(Pardridge et al., 1997; Abbott et al., 2006). Even with the availability of various transporting 
systems on the BBB, no such ‘transporter’ has been successfully used in transporting large 
molecules to the brain.  
A well accepted BBB model is a three-cell type model. In this model, the BBB comprises 
brain capillary endothelial cells, astrocytes and pericytes as shown in Figure 2.1 (Garberg et al., 
2005; Flaten et al., 2006; Pardridge et al., 1999).  
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Figure 2.1 Illustration of a cerebral capillary enclosed in astrocyte end-feet (Redrawn from 
http://www.answers.com/topic/blood-brain-barrier, cited December 6, 2011) 
2.2 Brain tumor 
Brain tumor is an intracranial mass produced as a result of an uncontrolled growth of cells 
either normally found in the brain such as neurons, lymphatic tissue, blood vessels, or from 
cancers primarily located in other organs. Brain tumors can be classified based on whether it is 
benign (non cancerous, do not invade or spread to surrounding tissues) or malignant (invasive), 
the location of the tumor or the type of tissue involved. 
Primary brain tumors are the tumors which originate in the brain. Secondary brain tumors 
originate from the tumor cells which spread to brain from another location in the body. These 
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mostly originate from organs like breast, kidney, lungs, renal or from melanomas in the skin 
(Sawaya et al., 2001). Primary brain tumor may be associated with edema and necrosis. Edema is 
generally found in the white matter regions around the tumor (Prastawa et al., 2005). By 
definition, brain edema is an increase in brain volume resulting from increased sodium and water 
content and results from local disruption of the blood brain barrier (BBB). Necrosis is composed 
of dead cells in the middle of the brain tumor. It is one of the leading causes of mortality 
resulting from brain tumors.  
Primary brain tumors can be further classified by tissue origin. The major primary brain 
tumor types based on tissue origin are summarized in Table 2.1 (CBTRUS, 2002; Doolittle et al., 
2004). On the basis of location tumors can be classified into 3 classes: local tumors, regional 
tumors and distant tumors. Local tumors are confined to one hemisphere in part of brain. 
Regional tumors are those which cross midline and invade bone, blood vessel, nerves and spinal 
cord. Distant tumors can extend up to the nasal cavity, nasopharynx and outside the CNS.  
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Table 2.1 Primary brain and CNS tumors by histology and percent reported (Redrawn from 
Doolittle, 2004) 
Histology % of Reported Brain Tumors 
Tumors of neuroepithelial tissue 48.1 
Glioblastoma 23.0 
Astrocytoma 4.2 
Anaplastic astrocytoma 3.7 
Oligodendroglioma 2.9 
Glioma malignant 2.7 
Others 10.6 
Tumors of the meninges 28.7 
Meningioma 27.4 
Other mesenchymal, benign and malignant 1.2 
Lymphomas and hematopoietic neoplasms 2.7 
Germ cell tumors and cysts 0.5 
Tumors of the sellar region 7.4 
Pituitary 6.6 
Craniopharyngioma 0.8 
Local extensions from regional tumors 0.2 
Unclassified tumors 5.0 
Hemangioma 0.4 
Neoplasm, unspecified 4.5 
Other 0.1 
Total 100.0 
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 2.3 Conventional and modern treatments 
Brain tumors can be treated by various methods including surgery, radiation therapy, 
chemotherapy, and drug delivery. In this section, conventional and modern treatment strategies 
for the treatment of brain tumors are discussed briefly. 
2.3.1 Surgery 
Surgery is usually the first step in brain tumor treatment. It is preferred to remove as much 
tumor as possible and to reduce the intracranial pressure. Surgical removal of brain tumors is 
expected to control tumor-induced seizures and is a necessary step before radiation and 
chemotherapy. Some tumors are difficult to resect when they are located at an inaccessible site 
such as brain stem and thalamus. If a large number of tumors are present or if their borders or 
edges are poorly defined, it will be more challenging for safe removal. Many other factors such 
as patient’s general health, neurological status, and history of recovery from surgery should be 
taken into consideration and can hinder surgery as an option for tumor removal (American Brain 
Tumor Association. Surgery Brochure, 2004). 
Surgery poses both general and specific risks. Common risks include infection, bleeding, 
blood clots, pneumonia and blood pressure instability. In addition, partial or complete loss of 
sensation, vision, movement, hearing or other functions are the possible consequences of 
surgery. Surgery on brain tumors located deep inside the brain is more challenging and 
potentially causes more serious side effects including seizures, weakness, spinal fluid leakage, 
brain swelling, stroke, coma, and even death (American Brain Tumor Association, Surgery 
Brochure, 2008). There are many different types of surgery for brain tumors as summarized in 
Table 2.2. 
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Table 2.2 Types of surgery with their procedure and purpose (based on American Brain Tumor 
Association, Surgery Brochure, 2008) 
 
Type of Surgery  Procedure and Purpose 
Biopsy To obtain tissue sample for pathology 
Needle biopsy Hole drilled into skull, sample tissue drawn up by 
hollow needle 
Stereotactic biopsy Computer-assisted needle biopsy 
Open biopsy Tissue sample taken during surgery 
Craniotomy Opening and removing a part of skull for surgery and 
replacement of removed skull  
Craniectomy Similar to craniotomy with bone not being replaced 
before closing incision 
Debulking Surgically reduce size of tumor 
Partial removal Partial removal of tumor, requires additional treatment 
Complete removal Gross total resection, tumor cells might remain 
Shunt Remove excess fluid, reduces intracranial pressure 
Ommaya Reservior Implanted container used to deliver chemotherapy, 
remove CSF and cystic fluid 
Skull base  Special technique to remove tumors in delicate bony 
area that supports the bottom of the brain 
Transphenoidal Incision is under the upper lip and over the teeth, or 
directly through the nostril 
 
2.3.2 Radiation therapy 
The purpose of radiation therapy is to control or prevent brain tumor growth. Radiation 
therapy is often used after surgery to treat inoperable tumors or metastatic tumors. It can also be 
applied during or after chemotherapy or along with drugs that make tumor cells more sensitive to 
radiation. In principle, radiation (x-rays, gamma rays, or photons) either kill tumor cells directly 
or interferes with their ability to grow (American Brain Tumor Association. Radiation therapy 
Brochure, 2004). Normal brain tissue can tolerate up to 60 Gy (Gray units) of radiation per dose, 
different tumors require different doses of radiation. For example, glioblastoma (GB), typically 
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receive 180-200 cGy (centi-Gray units) per dose, 5 days a week for 6 weeks, totaling 5400-6000 
cGy over the course of radiation therapy (Castro et al., 2003; American Brain Tumor 
Association, Radiation therapy Brochure, 2009). Like any other radiation treatment, brain tumor 
radiation causes side effects including fatigue, hair loss, changes in skin, swelling, nausea, sexual 
effects, blood clots and post-treatment depression. 
2.3.3 Chemotherapy  
Chemotherapy is the method to treat benign or malignant brain tumors with the use of drugs. 
There are different types of chemotherapy drugs available such as drugs that stop cells from 
starting the cycle, “targeted or biological agents”, and that which act during a particular phase of 
cell cycle, “cell-cycle specific” drugs. There are also some “non cell-cycle specific drugs” which 
are not cycle dependent.  Chemotherapy drugs can be delivered to the body via systemic or local 
delivery. Systemic delivery is where the drug is administered orally or injected into the body and 
circulates via bloodstream before it crosses the BBB and enters the brain. Local delivery places 
the drug within or near the tumor in the brain. This produces a higher concentration of drug at 
the tumor site and minimizes toxic effects on normal cells. Chemotherapy drugs are classified 
into two types - cytotoxic drugs causing cell death and cytostatic agents preventing cell division 
(American Brain Tumor Association. Chemotherapy Brochure, 2004). The subgroups of each 
type are summarized in Figure 2.2. 
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Figure 2.2 Classification of chemotherapy drugs (based on American Brain Tumor Association, 
Chemotherapy Brochure, 2009)  
Anti-tumor antibiotics stop the activity of enzymes needed for cell growth. One example is an 
anthracycline antibiotic, doxorubicin (DOX) (Figure 2.3). It is closely related to the natural 
product daunomycin. It intercalates with DNA (Beer et al., 2001) and stops the macromolecular 
biosynthesis (Fornari et al., 1994; Momparler et al., 1976). Topoisomerase II relaxes the DNA 
supercoils, after which DOX stabilizes the topoisomerase II complex thus inhibiting 
transcription. The aromatic portion of DOX intercalates with the base pairs of the DNA, whereas 
daunosamine sugar interacts with base pairs adjacent to intercalation site (Frederick et al., 1990; 
Pigram et al., 1972). 
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Figure 2.3 Structure of doxorubicin (Redrawn from DrugBank) 
The side effects of chemotherapy are closely related to the type of drug used. Common side 
effects include nausea, vomiting, sores in the mouth and throat, loss of appetite, diarrhea 
dizziness, hair loss and fatigue. Serious side effects include hives, skin rash, itching, difficulty 
breathing or swallowing, seizures, heart arrhythmias and neutropenia (decrease in white blood 
cells) (Castro et al., 2003; American Brain Tumor Society, Chemotherapy Brochure, 2009). 
Chemotherapy drugs can be delivered to the brain via different routes such as BBB disruption, 
blood or marrow stem cell transplantation, convention enhanced delivery (CED), high dose 
chemotherapy, intracavitary/ polymer wafer implants, interstitial therapies and reservoirs and 
pumps (American Brain tumor Society, Chemotherapy Brochure, 2009). Not all of the methods 
mentioned above have been adopted as standard methods. 
2.3.4 Drug delivery 
Nanotechnology and polymers have been applied to develop efficient and novel drug 
delivery systems. Some delivery strategies are shown in Table 2.3 (Jain et al., 2005). 
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Particularly, nanoparticulate drug delivery systems have drawn considerable attention. A variety 
of materials such as linear polymers, hyperbranched polymers, micelles, dendrimers and lipids 
can be used to make nanoparticulate drug delivery systems (Kwangjae et al., 2008). 
2.3.4.1 Polymer-based drug carriers 
Drugs can be either physically encapsulated or covalently conjugated to polymers (Rawat et 
al., 2006). Both natural and synthetic polymers have been used in drug delivery. 
2.3.4.1.1 Polymeric nanoparticles  
Albumin, chitosan and heparin are naturally occurring polymers, and they have been used to 
deliver drugs eg. Albumin-bound-paclitaxel (Abraxane) for metastatic breast cancer (Gradishar 
et al., 2005), non-small-cell lung cancer (phase II trial; Green et al., 2006) and nonhematologic 
malignancies (phase I, pharmacokinetics trials; Nyman et al., 2005). Side effects of 
chemotherapy drugs can be reduced through conjugation with synthetic polymers such as 
polymer poly-L-glutamic acid (PGA) and N-(2-hydroxypropyl)-methacrylamide copolymer 
(HPMA) (Li et al., 2002). PGA conjugated with taxol (Xyotax, Sabbatini et al., 2004) and with 
camptothecin (CT-2106, Bhatt et al., 2003) is in clinical trials. DOX conjugated with HPMA 
(PK1) is in clinical trial for treating a variety of tumors (Vasey et al., 1999). Recently, DOX 
conjugated with HPMA (HPMA-DOX, PK1) was further conjugated to galactosamine (HPMA-
DOX-galactosamine, PK2) and has cleared Phase I/II trials (Seymour et al., 2002) as mentioned 
in Table 2.4. 
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Table 2.3 Drug delivery strategies in cancer (Redrawn from Jain et al., 2005) 
Direct introduction of drug 
 Direct injection into tumor 
 Tumor necrosis therapy 
 Local injection for radio-potentiating 
 Electro-chemotherapy 
 Local delivery by implants 
Routes of drug delivery 
 Intraperitoneal 
 Intrathecal 
 Nasal 
 Oral 
 Subcutaneous injection/ implant 
 Trans-dermal drug delivery 
 Intravenous, intra-arterial vascular route 
Systemic targeted delivery 
 Heat-activated 
 Tissue-selective using carrier-mediated transport systems 
 Tumor-activated drug therapy 
 Pressure-induced filtration of drug across vessels to tumors 
 Two-step targeting using bi-specific antibody 
 Site-specific delivery 
 Light-activation  
Targeted to blood vessels of tumor 
 Antiangiogenesis therapy 
 Angiolytic therapy 
 Induce clotting 
 Vascular targeting agents 
Special formulations and carriers 
 Albumin-based carriers 
 Carbohydrate-enhanced chemotherapy 
 Protein and peptide delivery 
 Fatty acids as targeting vectors 
 Microspheres 
 Monoclonal antibodies 
 Nanoparticles 
 Pegylated liposomes 
 PEG technology 
 Single-chain antigen-binding technology 
Trans-membrane drug delivery to intracellular targets 
 Cytoporter 
 Receptor-mediated endocytosis 
 Transduction of proteins and peptides 
 Vitamins as carriers 
Biological therapies 
 Antisense therapy 
 Cell therapy 
 Gene therapy 
 Genetically modified bacteria 
 Oncolytic viruses 
 RNA interference 
15 
 
Table 2.4 Nanocarriers for drug delivery (Redrawn from Kwangjae et al., 2008) 
System Structure Characteristics Examples 
Polymeric 
nanoparticles 
Drug conjugated  to 
the polymer via 
cleavable linker  
 Hydrophilic, nontoxic, 
biodegradable 
 Possibility of surface modification 
(PEGylation) 
 Selective accumulation and 
retention in tumor tissue 
 Specific targeting of cancer cells 
 Albumin-Taxol, Abraxane 
(Gradishar, 2005) 
 PGA-Taxol, Xyotax 
(Sabbatini, 2004) 
 PGA-Camptothecin, CT-
2106 (Bhatt, 2003) 
 HPMA-DOX, PK1 
(Vasey, 1999) 
 HPMA-DOX-
galactosamine, PK2 
(Seymour, 2002) 
Polymeric 
micelles 
Amphiphilic block 
copolymers assemble 
to form hydrophobic 
core and hydrophilic 
shell micelles 
 Carriers for hydrophobic drugs 
 Biodegradable, biocompatible, self-
assembling 
 Functional modification 
 Targeting potential 
 PEG-pluronic-DOX 
(Batrakova, 1996) 
 PEG-PAA-DOX, NK911 
(Nakanishi, 2001) 
 PEG-PLA-Taxol, 
Genexol-PM (Kim, 2004) 
Dendrimers Systematic 
hyperbranched 
polymer with radially 
emerging pattern and 
repeated units 
 Tuning of biodistribution and PK 
 Chemical and structural 
homogeneity 
 Easy functionality and high ligand 
density 
 Controlled degradation 
 Multifunctional 
 PAMAM-MTX 
(Kukowska, 2005) 
 PAMAM-platinate (Malik, 
1999) 
Liposomes Lipid bilayers forming 
self-assembled closed 
colloidal structures 
 Targeting potential 
 Easy modification 
 Biocompatible, Amphiphilic 
 PEGylated liposomal 
DOX, Doxil (Markman, 
2006) 
 Non-PEGylated liposomal 
DOX, Myocet (Rivera, 
2003) 
 Liposomal daunorubicin, 
DaunoXome (Rosenthal, 
2002) 
Viral 
nanoparticles 
Multivalent self-
assembled protein 
cages 
 Modified surface by mutagenesis or 
bioconjugation 
 Tumor targeting 
 Uniformity and defined structure 
 Inert and biocompatible 
 HSP-DOX (Flenniken, 
2006, 2005) 
 CPMV-DOX 
(Manchester, 2006) 
Carbon 
nanotubes 
Carbon cylinder 
consisting benzene 
ring 
 Hydrophilic, biocompatible 
 Multifunctional 
 CNT-MTX (Pastorin, 
2006) 
 CNT-amphotericin B 
(Wu,2005) 
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2.3.4.1.2 Polymeric micelles (amphiphilic block copolymers) 
Micelles are made of amphiphilic block copolymers. These blocks form nanosized core/shell 
structures with a hydrophobic core and a hydrophilic shell in an aqueous media. The 
hydrophobic core helps with encapsulation of hydrophobic drugs (Adams et al., 2003).  
Polymeric micelle formulations of paclitaxel are in phase I and pharmacokinetic studies for 
patients with refractory malignancies as mentioned in Table 2.4 (Kim et al., 2004). MRI-
ultrasensitive imaging agents carrying multi-functional micelles have also been developed 
(Nasongkla et al., 2006). 
2.3.4.1.3 Dendrimers 
 Tomalia et. al. developed a class of nanoscale, highly branched, synthetic polymeric 
macromolecule known as dendrimers (Tomalia et al., 1985). Dendrimers have received 
significant attention for drug delivery because of its diverse properties: monodisperse size, 
modifiable surface functionality, multivalency, water solubility, hollow core and low 
polydispersity (Klajnert et al., 2007; Svenson et al., 2005). Polyamidoamine (PAMAM) 
dendrimers, most widely used for drug delivery, have either an ethylenediamine (EDA) or an 
ammonia core with methyl acrylate and ethylene diamine branches (Klajnert et al., 2007; 
Tomalia et al., 1985). They are commercially available as full generation (cationic) having amine 
terminal groups and half generations (anionic) having carboxyl terminal groups (Klajnert et al., 
2007). PAMAM dendrimer has been conjugated with cisplatin for sarcomas (Malik et al., 1999) 
and methotrexate (MTX) on animal models for epithelial cancer (Kukowska-Latallo et al., 2005) 
as mentioned in Table 2.4. 
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2.3.4.2 Lipid-based drug carriers 
Liposomes are closed colloidal structures made of self-assembled lipid bilayers. They have a 
spherical structure having a hydrophilic core. Many chemotherapeutic drugs can be delivered by 
liposomes. As summarized in Table 2.4, a few lipid formulations carrying DOX have been 
approved by FDA, e.g. Doxil (Markman et al., 2006) for treatment of ovarian cancer, Myocet 
(Rivera et al., 2003) for treatment of metastatic breast cancer and with daunorubicin such as 
DaunoXome (Rosenthal et al., 2002) for treatment of AIDS-related Kaposi’s sarcoma (Markman 
et al., 2006; Rivera et al., 2003; Rosenthal et al., 2002). 
2.3.4.3 Viral nanoparticles 
Researchers have developed virus-based vehicles such as mosaic virus, canine parvovirus for 
tissue and drug targeting. Specific in vivo tumor targeting has been achieved by conjugating 
ligands or antibodies such as transferrin, folic acid to viruses (Manchester et al., 2006). Canine 
parvovirus has a natural affinity for transferrin receptor up-regulated in tumor cells (Singh et al., 
2006) as summarized in Table 2.4. 
2.3.4.4 Carbon nanotubes 
Carbon nanotubes are cylindrical structures made of benzene rings (Bianco et al., 2005). 
Carbon nanotubes have found applications for detection of DNA (Cai et al., 2003; Wang et al., 
2004; Williams et al., 2002), discrimination of protein (Gooding et al., 2003; Wang et al., 2004), 
ion channel blockers (Park et al., 2003), and drug/ vaccine delivery (Bianco et al., 2005). 
However, carbon nanotubes have low water solubility and can cause toxicity. Surface 
modification can improve their water solubility and biocompatibility (Bianco et al., 2005). In 
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vitro studies involving carbon nanotubes have been promising for drug delivery (Wu et al., 2005; 
Pastorin et al., 2006). Presence of multiple functionalities on the sidewalls allows them to carry 
different molecules e.g., drugs and fluorescent agents (Pastorin et al., 2006) at once, thus 
providing a fundamental advantage for cancer treatment. Methotrexate (Pastorin et al., 2006) and 
amphotericin B (Wu et al., 2005) that were conjugated to carbon nanotubes showed more 
efficient cellular internalization compared to free drug. 
2.3.4.5 Drug delivery using monoclonal antibodies 
Monoclonal antibodies (MAb’s) can function as diagnostic agent and/or therapeutic agent 
(Jain et al., 2005). Several MAb’s have been approved by FDA for cancer treatment. For 
example, Cetuximab (Erbitux, CTX) is a chimeric monoclonal antibody of immunoglobulin G1 
class, against the human epidermal growth factor receptor (EGFR) (Baselga et al., 2001; 
Goldstein et al., 1995; FDA, 2004). CTX has been recently approved by the FDA as an anti-
cancer agent for colorectal (FDA, 2004) and head & neck cancers (FDA, 2011). EGFR is over 
expressed in more than 35% of all solid malignant tumors (Salomon et al., 1995). EGFR is one 
of the members of the erbB family of receptor tyrosine kinases. It can be divided into an 
extracellular domain that can bind ligands, a trans-membrane domain and an intracellular 
tyrosine kinase domain (Yarden et al., 2001). When a ligand binds to EGFR, it causes receptor 
dimerization leading to tyrosine kinase activation and receptor autophosphorylation which in 
turn initiates signal-transduction pathways. These pathways are involved in proliferation and 
survival of cell (Yarden et al., 2001). CTX competitively binds to EGFR and blocks the binding 
site of ligand. This inhibits dimerization & receptor phosphorylation, thus stopping downstream 
signaling pathway (Kirkpatrick et al., 2004). The EGFR working mechanism and CTX blocking 
is mentioned in Figure 2.4.  
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Figure 2.4 Schematic diagram representing mode of action of EGFR and CTX (Redrawn from 
Kirkpatrick et al., 2004) 
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CHAPTER 3 MATERIALS AND METHODS 
3.1 Materials and reagents 
Table 3.1 List of materials and reagents used 
Material Abbreviation Source 
Polyamidoamine dendrimer generation 4.5 G4.5 Sigma Aldrich 
N-hydrosuccinimide NHS Fluka  
1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) 
EDC Sigma Aldrich 
Amine Polyethylene glycol-maleimide NH2-PEG-mal Jen-Kem 
N-methylmorpholine NMM Acros 
N,N-dimethylformamide DMF Sigma Aldrich 
Isobutyl chloroformate IBCF Acros 
Carbazic acid-tert-butyl ester Cat-BE Sigma Aldrich 
Doxorubicin DOX Sigma Aldrich 
Trifluoroacetic acid TFA Sigma Aldrich 
Methanol MeOH Sigma Aldrich 
Cetuximab CTX Gifted from Dr. Michael H. Peters’s Lab, 
Chemical and Life Science Engineering, VCU  
Traut’s reagent  Thermo Scientific 
De-ionized water DI water  
Diethyl ether Ether EMD Chemicals 
Sodium bicarbonate solution NaHCO3 Sigma Aldrich 
Phosphate buffer saline PBS Sigma Aldrich 
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3.2 Equipment  
Table 3.2 List of equipment and machines used 
Equipment name Use 
Rotary evaporator, Heidolph LABOROTA 4000 Distillation of low boiling point chemicals from mixture of 
compounds 
Flexi-dry MP controlled rate freezer, FTS Systems, 
Inc. 
Freeze drying the samples 
Weighing scale Measuring quantity of chemicals 
Eppendorf centrifuge model-5415D Density based separation of compounds in a mixture 
Bruker AVANCEIII 600 MHz, Nuclear Magnetic 
Resonance (NMR) spectrometer 
Measuring chemical shifts of protons, 
1
H-NMR 
Malvern’s Zetasizer Nano ZS90 Measurement of hydrodynamic radius and molecular 
weight of nanoparticle and electrokinetic potential in 
colloidal system 
Genesys 6 UV-Vis spectrophotometer Quantitative analysis of drug release study and gel 
filtration chromatography 
Zeiss Invertoskop 40C Microscope Examining cell growth and for cell counting 
Nexcelom Bioscience Cellometer ® Auto T4 Automated cell counting 
Zeiss Axiovert 200 M fluorescence microscope Examining of cellular uptake 
Beckman Coulter DU® 640 Spectrophotometer Measurement of protein content in cell lysis studies 
Incubator Temperature and humidity control of cell culture 
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3.3 Experimental methods 
3.3.1 Preparation of maleimide bearing PEGylated G4.5 dendrimer (mal-PEG-G4.5) 
Maleimide bearing PEGylated PAMAM dendrimer G4.5 (mal-PEG-G4.5) was synthesized 
by substituting the carboxyl group present on G4.5 PAMAM dendrimer (MW = 26258 dalton) 
with NH2-PEG-mal (MW = 3500 dalton) group as described in a previously reported method 
(Yang et al., 2003). As shown in Figure 3.1, after removal of methanol from G4.5 stock solution 
by rotary evaporation, 0.5 µmol of G4.5 was dissolved in 2ml of DMF. To this solution, 12.8 
µmol of EDC and 12.8 µmol of NHS at the feed molar ratio of 25.6:25.6:1 for EDC: NHS: G4.5; 
(20% w.r.t. G4.5) was added. After an overnight reaction while stirring at room temperature, the 
resultant G4.5-NHS was precipitated in excess amount of cold diethyl ether. The precipitate was 
re-dissolved in DI water and then rotary evaporated to obtain G4.5-NHS. The obtained G4.5-
NHS and NH2-PEG-mal (2 µmol) were dissolved in 2ml and 1ml of 0.1 M NaHCO3 solution (pH 
8.5) respectively. NH2-PEG-mal containing NaHCO3 solution was dropwise added to the G4.5-
NHS solution. The mixture was stirred for 3-4 hours at room temperature and the resulting 
conjugates were dialyzed in DI water using dialysis cassette of MWCO 10K. The purified 
solution was dried using rotary evaporator to obtain mal-PEG-G4.5. 
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Figure 3.1 Preparation of mal-PEG-G4.5 
3.3.2 Conjugation of doxorubicin to G4.5-PEG-mal 
DOX was covalently attached to the remaining carboxyl groups on the dendrimer surface of 
G4.5-PEG-mal. The polymer-DOX conjugates via acid sensitive hydrazone linkage was 
synthesized as previously reported (Bae et al., 2003; Lai et al., 2007) 
As shown in Figure 3.2, 54.4µmol of Cat-BE at a feed molar ratio of Cat-BE: G4.5 as 1:1 
(85% of G4.5) and G4.5-PEG-mal were dissolved in 5ml of DMF respectively. 272 µmol of 
NMM was added to G4.5-PEG-mal solution (5 times of 85% of G4.5 molar quantity). 272 µmol 
of IBCF (5 times of 85% of G4.5 molar quantity) was added dropwise at 4°C and the mixture 
was kept for five minutes was added. After this the Cat-BE solution was added dropwise to this 
solution. The mixture was allowed to react for thirty minutes at 4°C and two more hours at room 
temperature.  
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The white sediments of the by-product formed were removed by centrifuging the solution for 
10 minutes at 10,000 rpm. The supernatant was added dropwise to diethyl ether and kept at -20 
°C overnight. The precipitate was collected by centrifuging the ether solution for 10 minutes at 
10,000 rpm and then re-dissolved in 3ml of PBS (pH 7.4). The product was purified in PBS (pH 
7.4) using a dialysis cassette of MWCO 10K. mal-PEG-G4.5-hyd-BOC was obtained after rotary 
evaporating the solution. The synthesized mal-PEG-G4.5-hyd-BOC was further treated with 1ml 
trifluoro acetic acid (TFA) to remove the BOC protective groups. An excess amount of DOX 
(65.28 µmol) was added in 20ml of methanol with TFA as an acid catalyst. The solution was 
stirred for 24 hours in dark. The solution was further concentrated to 2ml and then dialyzed in 
PBS (pH 7.4) with a dialysis cassette MWCO 7K. The product was further purified using a PD-
10 desalting column. The purified product was obtained after rotary evaporation. 
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Figure 3.2 Conjugation of DOX to G4.5-PEG-mal via hydrazon linkage 
3.3.3 Conjugation of Cetuximab to mal-PEG-G4.5-DOX 
CTX was thiolated using a similar procedure reported earlier for anti-rat transferrin receptor 
OX26 mAb (Huwyler et al., 1996). According to Figure 3.3, 0.06 nmol CTX was dissolved in 
0.15 M sodium borate buffer/ 0.1 mM EDTA (pH 8.5) with 2.4 nmol of 2-iminothiolane, Traut’s 
reagent (2-iminothiolane : CTX molar ratio 40:1) for 60 minutes in dark at room temperature. 
Afterwards, 0.03 nmol mal-PEG-G4.5-DOX was added to the thiolated CTX mixture to react 
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overnight with gentle shaking. The mixture was concentrated using a rotary evaporator and 
purified using Sephacryl S-200 HR column. 
 
 
Figure 3.3 Conjugation of CTX to mal-PEG-G4.5-DOX 
3.4 Characterization 
3.4.1 Proton nuclear magnetic resonance spectroscopy (
1
H-NMR) 
1
H-NMR spectroscopy was performed on Brucker AVANCE III 600 MHz NMR 
spectrometer with D2O as the solvent. The data obtained was processed using MestReNova 
NMR software (licensed software) from Mestrelab research. The chemical shift of D2O residue 
was observed at 4.8 ppm. 
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3.4.2 Fluorescence anisotropy 
Anisotropy was performed to confirm the conjugation of doxorubicin to mal-PEG-G4.5. 
Doxorubicin is a fluorescent molecule. Fluorescent molecules when struck with polarized light 
result in polarized fluorescence (Ingersoll et al., 2007). The rotational diffusion of the 
fluorophore during the excited lifetime is the main cause of this depolarized fluorescence. Thus 
by measuring these fluorescence polarizations, the rotational mobility of the fluorophore can be 
easily determined. Anisotropy is the technique to experimentally find out fluorescence 
depolarization. It is directly related to the polarized-light component and inversely to total light 
intensity.  A schematic diagram representing basic “L-format” fluorescence polarization is 
shown in Figure 3.4. The sample is first excited using a vertically polarized light and thus the 
intensity component with both excitation and emission polarizer mounted vertically (IVV) and 
intensity component with excitation polarizer vertical and emission polarizer horizontal (IVH) are 
measured.  
Anisotropy (r) is given as (Lackowicz et al., 2006) 
                                                           
VHVV
VHVV
IGI
IGI
r
**2
*


                                                            Eq. 1 
where G, “G-factor” is the ratio of the intensity component with excitation polarizer horizontal 
and emission polarizer vertical (IHV) to intensity component with both excitation and emission 
polarizers mounted horizontally (IHH).  
                                                          G = 
HH
HV
I
I
                                                                          Eq. 2 
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It is dependent on the slit width as well as the monochromator wavelength.   
Polarization, P can be found out using  
P = 
r
r
2
3
                                                                     Eq. 3 
Samples of both free doxorubicin, 0.01 mg, and mal-PEG-G4.5 bound doxorubicin, 0.01 mg 
equivalent doxorubicin, were prepared in 1 ml of methanol. The measurements were made using 
a Cary Eclipse Fluorescence spectrophotometer equipped with an 80 Hz Xenon arc lamp, R928 
detector and was operated at 600V. The maximum excitation was found at a wavelength of 480 
nm with maximum emission at a wavelength of 585 nm at room temperature.  
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Figure 3.4 Schematic representation of “L-format” fluorescence polarization with vertical (V) 
and horizontal (H) orientations of polarizer (Redrawn from Ingersoll et al., 2007). 
 
3.4.3 Ultraviolet-visible spectroscopy (UV-Vis) 
UV-Vis spectroscopy was performed to calculate the amount of DOX attached to mal-PEG-
G4.5. DOX stock solution was prepared by dissolving 1 mg of DOX in 1 ml of 1X PBS (pH 7.4). 
Five serial dilutions; 1, 0.5, 0.25, 0.125 and 0.062 mg/ml, were prepared to generate a standard 
curve, given in Figure 3.5, using a Genesys 6 UV-Vis spectrophotometer. 1.7 mg of mal-PEG-
Sample 
 
Light source V 
H 
 
V 
H 
Excitation beam 
Fluorescence emission 
Detector 
Excitation polarizer 
Emission polarizer 
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G4.5-DOX was dissolved in 1 ml of 1X PBS. The absorbance of this mixture was measured at 
480 nm. The absorbance value of mal-PEG-G4.5-DOX was compared to the standard curve of 
DOX. The amount of DOX conjugated was calculated as follows. Using the absorbance (A) 
determined by UV-Vis spectrophotometer and the equation of line obtained from standard curve, 
the concentration of DOX was calculated, which gave the amount of DOX in the mal-PEG-G4.5-
DOX sample by  
Concentration of DOX  mlmg / = 
)(
)(
mlsolutionofAmount
mgDOXofAmount
                       Eq. 4 
This amount of DOX in mg was converted to amount in moles by 
Amount of DOX (mol) = 
)/(
)(
molmgDOXofWeightMolecular
mgDOXofAmount
                    Eq. 5 
where, molecular weight (MW) of DOX = 580 g/mol. Amount of mal-PEG-G4.5 in sample was 
calculated as,  
Amount of mal-PEG-G4.5 (mg) = Amount of sample (mg) – Amount of DOX (mg)          Eq. 6 
 
                   Amount of mal-PEG-G4.5 (mol) = 
)/(5.4
)(5.4
molmgGPEGmalofMW
mgGPEGmalofAmount


              Eq. 7 
The amount of DOX attached to mal-PEG-G4.5 was calculated as a molar ratio,                                  
                                            
)(5.4
)(
molGPEGmalofAmount
molDOXofAmount

                                         Eq. 8 
The same standard curve and UV-Vis spectroscopy was later used for analyzing doxorubicin 
release kinetics from the G4.5-DOX conjugate. 
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Figure 3.5 Standard curve of DOX 
3.4.4 Western blotting 
Western blotting is widely used to detect expression of specific protein based on size 
separation under gel electrophoresis. The protein sample is dissolved in sodium dodecyl sulphate 
(SDS) buffer. SDS buffer is an anionic detergent, which quantitatively binds to proteins. This 
binding gives them linearity and a uniform charge, thus they can be separated only based on size 
(Burnette et al., 1981).  Addition of mercaptorethanol in the buffer reduces any disulphide bonds 
within the protein. Western blotting can also be used to approximate the molecular weight of a 
protein or a protein conjugate. Samples are loaded into wells in the running gel. One lane 
generally contains MW markers, a mixture of proteins of defined molecular weights. Analysis of 
the molecular weight is done after electroblotting the separated protein onto a nitrocellulose or 
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polyvinylidene difluoride membrane and then photographed. Size approximations are done by 
referencing the bands of proteins to those of the marker (Burnette et al., 1981). 
To confirm the coupling of CTX to mal-PEG-G4.5-DOX, western blotting was performed. 
Free CTX and CTX-PEG-G4.5-DOX containing CTX equivalent concentration of 10 nmol were 
dissolved in 20 µl PBS buffer. This mixture was then dissolved in 6X SDS sample loading buffer 
(375 mM Tris, pH 6.8, 10% SDS, 50% Glycerol, 10% B-mercaptoethanol, 0.03% Bromophenol 
Blue). Protein samples were run on 8% Tris/ Glycine SDS-polyacrylamide gel (120 minutes, 120 
V, room temperature). The proteins were electroblotted using 1X- transfer buffer with 20% 
methanol (5 mA, overnight, room temperature) on to a polyvinylidene difluoride (PVDF) 
membrane (Immobilon-P; Millipore, Billerica, MA) . The membrane was blocked for unspecific 
binding with 5% non-fat dry milk (1h, room temperature) in Tris-buffered saline. Then, 
membranes were incubated (1h, room temperature) in blocking buffer with IgE antibodies 
against cetuximab (1:1000 dilutions). After washing in TTBS, cetuximab were detected using 
Western Lightning Enhanced Chemiluminescence (ECL; Perkin-Elmer, Waltham, MA). 
3.4.5 Size and zeta potential measurements 
Molecules in suspension undergo Brownian motion. When such molecules are illuminated 
with a light source, laser in this case, depending on the size of the particles, the intensity of the 
scattered light fluctuates (http://www.malvern.com/labeng/technology/dynamic_light_scattering 
/dynamic_light_scattering.htm, January 19, 2012).  
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The velocity of Brownian motion is calculated using these intensity fluctuations and hence 
the hydrodynamic diameter, dH, is calculated using the Stokes-Einstein equation 
D
kT
dH
3
                                                            Eq. 9 
where, k is the Boltzmann constant, T is the temperature, η is the absolute zero-shear viscosity of 
the medium and D is the diffusion coefficient (Berne et al., 2000). 
Particles in aqueous systems generally acquire a surface charge which can be either by 
surface group ionization or charged species adsorption (http://www.malvern.com/labeng/technol 
ogy/zeta_potential/zeta_potential_LDE.htm, January 19, 2012). The liquid layer exists in two 
parts around the diffused particle; an inner region of strongly bound ions (Stern layer) and an 
outer of loosely bound ions (Diffuse layer). The ions and particles move within the boundary of 
the diffuse layer. When the particle moves due to Brownian motion, the ions move with it. The 
point in this layer where the potential moves past the bulk solution is called the zeta potential. A 
schematic representation of zeta potential is shown in Figure 3.6. 
An electric field is applied across the dispersion medium in order to measure zeta potential. 
The particles in the dispersion will move towards the oppositely charged electrode with a 
velocity proportional to the magnitude of the zeta potential. The velocity is measured by laser 
Doppler anemometry. As these particles are moving they cause a phase shift of the incident laser, 
which is measured as particle mobility. With the use of dispersant viscosity and use of 
Smoluchowski or Huckel theory, this mobility is converted to zeta potential (Smoluchowski et 
al., 1903). 
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Dynamic light scattering (DLS) and zeta potential studies were conducted using a Zetasizer 
Nano ZS90 equipped with a He-Ne laser from Malvern Instruments (Saovapakhiran et al., 2009). 
The hydrodynamic radius and zeta potential of G4.5 PAMAM dendrimer and the synthesized 
products including mal-PEG-G4.5 and mal-PEG-G4.5-DOX were determined. 1X PBS was used 
as the solvent and filtered through Whatman- Anotop 25 plus, 0.02 μm syringe filter. Samples 
were prepared by dissolving 1 mg of G4.5, 1 mg of mal-PEG-G4.5 and 1 mg of mal-PEG-G4.5-
DOX each in 1 ml of PBS and vortexed for proper mixing.  All measurements were taken at 
37˚C.  
 
Figure 3.6 Schematic representation of zeta potential (redrawn from http://www.malvern.com/ 
labeng/technology/zeta_potential/zeta_potential_LDE.htm, January 19, 2012) 
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3.4.6 DOX release studies 
The release of DOX from G4.5-DOX was studied at different pHs. 10 mg of CTX-PEG-
G4.5-DOX in 10 ml of PBS (pH 7.4, 37°C) was sealed in a dialysis bag (MWCO 1000). The 
dialysis bag was then submerged in 30 ml of PBS (pH 7.4) in a capped glass bottle and was 
incubated at 37°C for 192 hours. The released DOX in the incubation buffer was analyzed at pre-
determined time intervals up to 192 hours. At every time point, 1 ml aliquot of incubation buffer 
was transferred to a micro-centrifuge tube for doxorubicin content analysis. 1 ml of fresh PBS 
(pH 7.4) was added to the glass bottle to maintain the volume of incubation buffer. The same 
procedure was repeated for drug release studies at pH 4.5 and pH 5.5. Doxorubicin was 
quantified using a UV-Vis spectrophotometer at 480 nm. The standard curve of doxorubicin 
(Figure 3.5) was used as a reference to calculate the concentration of doxorubicin in each aliquot.  
Cumulative release of doxorubicin released was calculated as follows: 
% Cumulative release (t) = 100
0
1
1
1
30





W
ml
n
i
i
Ctml
n
Ct
                    Eq. 10 
where, Ctn is drug concentration in release medium at time t and W0 is initial amount of DOX in 
the sample (mg). 
3.4.7 Cell culture 
HN12 cells derived from metastatic squamous cell carcinoma were obtained from Dr. 
Andrew Yeudall’s lab, School of Dentistry, VCU. HN12 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and 
penicillin-streptomycin (100 units/ml). Cells were grown at 37˚C in a humidified atmosphere 
containing 10% CO2 (Yeudall et al., 1994). 
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3.4.8 Cytotoxicity assay 
Cytotoxicity of CTX-PEG-G4.5-DOX conjugates was evaluated. HN12 cells were seeded in 
a twenty-four-well cell culture plate at a density of 5x10
3
 cells/well. After 24 hours of culture, 
CTX-PEG-G4.5-DOX conjugates and free DOX at DOX equivalent concentrations of (100, 10 
and 1 nmol) were added. The cell viability was assessed in triplicates at 24, 48 and 72h 
respectively with the Trypan blue exclusion assay (Strober et al., 2001). The cells were counted 
using a Nexcelom Biosciences, Cellometer Auto T4 Cell Counter. 
3.4.9 DOX uptake studies 
HN12 cells were seeded at a density of 5x10
3
 cells/well in a twenty-four-well cell culture 
plate or on a 18 mm-diameter glass cover slip positioned in a twelve-well cell culture plate for 
fluorescence imaging. After 24 hour culture at 37°C, free DOX and CTX-PEG-G4.5-DOX 
conjugates at DOX equivalent concentration of 10 nmol were added to the wells. Cells were 
incubated for 6 hours, after which they were washed twice with ice cold 1X DPBS buffer. The 
cells treated with free DOX or CTX-PEG-G4.5-DOX were then fixed to the cover slip with 
100% methanol. After adding DAPI (50µg/ml, diluted to 1:4000) the cover slip was mounted on 
a glass slide using Vectashield H-1000 mounting medium and fixed with transparent nail polish. 
The cover slip was examined with a Zeiss Axiovert 200M inverted microscope at the VCU 
Philips Institute of Oral and Craniofacial Molecular Biology at VCU School of Dentistry. Image 
analysis was performed using Carl Zeiss Imaging Systems software. 
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For cell lysis, cells cultured on the plate and treated with free DOX and CTX-PEG-G4.5-
DOX conjugates were washed twice with ice cold 1X DPBS buffer and then lysed on ice for 10 
minutes using 110 µl of cell lysis buffer (20 mM HEPES, pH 7.5, 10 mM EGTA, pH 8.0, 40 mM 
β-glycerophosphate, 1% NP-40, 2.5 mM MgCl2, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 1 mM 
PMSF). Cells were immediately scraped and transferred to sterile 1.5 ml microcentrifuge tubes. 
The microcentrifuge tubes were centrifuged for 10 minutes at 12,000 rpm at 4°C. 5 µl of the 
supernatant was transferred to fresh microcentrifuge tube containing 795 µl of DI water and 200 
µl of Bio-Rad blue dye. This mixture was transferred to disposable cuvette the absorbance of 
protein was measured on a Beckman Coulter DU
®
 640 Spectrophotometer at 600 nm. A mixture 
of 800 µl of DI water and 200 µl of Bio-Rad blue dye was used as blank. The protein content 
was quantified using a modified Bradford assay (BCA; Biorad, Hercules, CA). The amount of 
DOX taken up by the cells was quantified using a Cary Eclipse Fluorescence spectrophotometer 
with an excitation wavelength of 480 nm and an emission wavelength of 585 nm.  
3.4.10 Statistical analysis 
Statistical analysis was performed on anisotropy, hydrodynamic radius, zeta potential, and 
cytotoxicity studies. All the statistical analysis was based on one way analysis of variance 
(ANOVA: Single Factor) and Tukey’s test on SigmaPlot software. A p-value less than 0.05 was 
considered statistically significant for rejecting the null hypothesis. Recording and analysis of 
data and its graphical representation were done in Microsoft Excel 2007, where the error bars 
represent standard deviations. 
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CHAPTER 4 RESULTS AND DISCUSSION 
4.1 Preparation and characterization of mal-PEG-G4.5 
Bi-functional mal-PEG-NH2 was conjugated to G4.5 based on EDC/NHS chemistry. 20% of 
carboxyl surface groups of G4.5 were activated using EDC with NHS. The amine group is highly 
reactive towards activated carboxyl. Activated carboxyl and amine groups form an amide linkage 
between mal-PEG and G4.5. 
The conjugation of mal-PEG and G4.5 was confirmed by 
1
H-NMR. In the 
1
H-NMR of mal-
PEG-G4.5 conjugate (Figure 4.1), the methylene proton peak of PEG (δ 3.69 ppm), multiple 
proton peaks of G4.5 (δ 2.19-3.47 ppm) and maleimide proton peak of PEG (δ 6.69 ppm, very 
dim signal) indicated the success of the synthesis of PEGylated dendrimer conjugates. 
Corresponding peak area was integrated to determine the number of PEG molecules per G4.5 
and hence approximate molecular weight of mal-PEG-G4.5 conjugate was calculated (Yang et 
al., 2006). It was determined that an average of 1.6 PEG chains was coupled to every G4.5 
molecule. The approximate molecular weight of mal-PEG-G4.5 conjugate was calculated to be 
31,858 g/mol. 
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Figure 4.1 
1
H-NMR spectrum of mal-PEG-G4.5 
4.2 Preparation and characterization of mal-PEG-G4.5-DOX 
Hydrazon groups were attached to the G4.5 dendrimer via an acid anhydride reaction as 
mentioned in Figure 3.2 (Bae et al., 2003; Lai et al., 2007). Synthesized mal-PEG-G4.5-Hyd-
BOC was treated with trifluoro acetic acid (TFA) to remove the BOC protective groups. DOX 
was then attached to the hydrazon residues of the mal-PEG-G4.5-Hyd through an imine, the 
Schiff base bond as mentioned in Figure 3.2 (Bae et al., 2003; Lai et al., 2007). The formed mal-
PEG-G4.5-DOX was dialyzed with PBS (pH 7.4) and applied to a PD-10 column for further 
purification. 
The conjugation of DOX to mal-PEG-G4.5-Hyd was confirmed using fluorescence 
anisotropy. Fluorescence anisotropy is measure of the fluorescence depolarization of fluorescent 
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molecules (Ingersoll et al., 2007; Lakowicz et al., 2006). Since fluorescence depolarization is 
caused by rotational diffusion of the fluorophore during its excited lifetime, the rotational 
mobility of the fluorophore can be determined with the help of anisotropy, r. If a molecule is 
freely suspended, it will have a faster rotational diffusion, thus a lower anisotropy value. Thus if 
it is bound to a large molecule, the rotational diffusion of the fluorophore will decrease and thus 
anisotropy should increase (Ingersoll et al., 2007). DOX is a fluorophore with an excitation 
wavelength at 480 nm and an emission wavelength at 585 nm in methanol. The anisotropy of 
free DOX was found to be 0.032 ± 0.001. The anisotropy value increased by 60% to 0.054 ± 
0.002 for DOX-G4.5-PEG-mal (n=6, with each run having 800 internal averages). The increased 
anisotropy was attributed to the conjugation of DOX to a large molecule mal-PEG-G4.5 (MW = 
31,858) and hence confirmed the conjugation of PEGylated dendrimer to doxorubicin. 
Significant statistical difference was found between the two anisotropy values with p<0.05. 
The amount of DOX attached to PEGylated dendrimer was calculated using UV-Vis 
spectroscopy. 1.7 mg/ ml of DOX-G4.5-PEG-mal in 1X-PBS gave an absorbance of 0.666 (n=3) 
and according to the standard curve of doxorubicin (Figure 3.5) the concentration of DOX in this 
sample was calculated using Eq. 4 and Eq. 5 to be 0.277 mg/ml or 0.479 µmol/ml. Using the 
molecular weight of mal-PEG-G4.5 as 31,858 g/mol, calculated earlier, their number of mole in 
the 1.7 mg/ml sample were calculated using Eq. 6 and Eq. 7 and were found to be 0.045 
µmol/ml. Using Eq. 8, it was calculated that approximately 10.7 molecules of DOX were 
attached per G4.5-PEG-mal molecule. 
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4.3 Preparation and characterization of CTX-PEG-G4.5-DOX 
EGFR is over-expressed in more than 35% of all solid malignant tumors (Salomon et al., 
1995) but is very weakly expressed and almost undetectable in the normal brain (Sauter et al., 
1996; Schwechheimer et al., 1995). This makes the EGFR an attractive option for targeted 
delivery of therapeutics to gliomas. Liposomes and PLA micelles have been conjugated with 
CTX for EGFR selective targeting previously (Pan et al., 2007; Liu et al., 2009). Anti-EGFR 
monoclonal antibody CTX was assembled on the G4.5 surface via PEG spacer. Thiolated CTX 
(Pan et al., 2007; Liao et al., 2010) have proved to be efficient in coupling with maleimide-
bearing polymer. As thiolation happens on the carbonate part of the Fc portion, the EGF receptor 
recognizing ability of CTX is preserved (Pan et al., 2007). CTX was first thiolated with Traut’s 
reagent (2-iminothiolane, Marsh et al., 1988) (Pan et al., 2007; Huwyler et al., 1996). An 
optimum 2-iminothiolane/ CTX molar ratio of 40:1 was used which on an average yields 
thiolation of one primary amine per CTX (Huwyler et al., 1996). The thiolated CTX to 
maleimide molar ratio was kept at 2:1 to yield an average of one CTX molecule per mal-PEG-
G4.5-DOX molecule. Success of conjugation of CTX to maleimide bearing dendrimer via PEG 
linker was confirmed using Western blotting (Figure 4.2). Using Western blot, the molecular 
weight of CTX-PEG-G4.5-DOX was calculated to be around 190 kDa. This molecular weight 
indicated that on an average, 1 CTX was conjugated to mal-PEG-G4.5-DOX. Using the 
molecular weights (CTX 150kDa, mal-PEG-NH2 3500 Da, G4.5 26258 Da and DOX 580 g) and 
molar ratios (CTX:PEG: G4.5: DOX as 1:1.6:1:10.7) mathematically the molecular weight of 
CTX-PEG-G4.5-DOX molecule comes out to be 188 kDa, which is equivalent to that indicated 
by Western blot. 
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Figure 4.2 Western blot of CTX-PEG-G4.5-DOX (lane 1) and free CTX (lane 2) 
 
4.4 Particle size and zeta potential 
Dynamic light scattering (DLS) was used to determine the particle size and zeta potential of 
the conjugates. The reaction chemistry involves multiple reactions and different types of 
functional moieties, which can lead to undesired cross-reactions. To avoid these unwanted 
reactions, CTX-PEG-G4.5-DOX conjugate was developed based on a 3-step layer-by-layer 
design. The first layer composed of mal-PEG conjugated to dendrimer. The second layer 
consisted of conjugation of DOX on the G4.5 surface. The third functional layer of CTX was 
assembled on the G4.5 surface via the PEG spacer attached earlier. The hydrodynamic size and 
zeta potential determined from DLS are summarized in Table 4.1. Coupling of different moieties 
to the G4.5 surface resulted in a consecutive increase in size and change in zeta potential. The 
success of the surface modifications is clearly reflected by the changes of size and zeta potential. 
The size of G4.5 was found to be 3.24 ± 0.46 nm which increased to 5.63 ± 0.23 nm with the 
addition of mal-PEG on its surface. mal-PEG-G4.5-DOX showed a measurable size of 39.78 ± 
150 kDa 
1                    2 
190 kDa     
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0.37 nm, a 12-fold increase after the addition of DOX as compared to G4.5. This significant 
increase in size can be linked with the addition of mal-PEG and DOX on the dendrimer surface 
and also can be attributed to flocculation of particles due to mal-PEG chain entanglement. As the 
surface of G4.5 was modified, the zeta potential changed from -21.02 ± 0.35 mV for G4.5 to -
2.53 ± 0.16 mV for mal-PEG-G4.5-DOX. All the conjugate groups showed significant statistical 
difference with each other with p<0.05. 
Table 4.1 Size and zeta potential of the tested conjugates in pH 7.4 PBS at 37°C 
Conjugates Size (nm, n=10) (p<0.05) Zeta Potential (mV, n=10) (p<0.05) 
G4.5 3.24 ± 0.46 -21.02 ± 0.35 
mal-PEG-G4.5 5.63 ± 0.23 -18.08 ± 0.95 
mal-PEG-G4.5-DOX 39.78 ± 0.37 -2.53 ± 0.16 
     
4.5 Release kinetics of DOX 
Enhanced permeability and retention effect (EPR) plays an important role in tumor targeting 
in body (Maeda et al., 1989). Macromolecules are engulfed by the cells via endocytosis (Bae et 
al., 2003). The endocytic pathway undergoes a pH change from 7.4 to 4.5 (Zhu et al., 2010). 
Release of DOX can be triggered by low pHs. DOX released from DOX-G4.5-PEG-CTX 
conjugates was measured at different pHs to evaluate the pH sensitivity of the hydrazon linkage 
between G4.5 and DOX. The pH values of the buffers were chosen as 7.4 (normal blood), 5.5 
and 4.5 (endosomal/lysosomal pH) for DOX release. As shown in Figure 4.3, DOX released 
from DOX-G4.5-PEG-CTX was pH dependent. Less than 20% of DOX was released at pH 7.4 
over a period of 192 hours, indicating that DOX-G4.5-PEG-CTX conjugates would be stable in 
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the blood stream. At pH 5.5 a total of 30% drug was released in 192 hours, whereas almost 90% 
of the DOX conjugated to G4.5 released in 192 hours at pH 4.5. This proved the success of 
attaching DOX via an acid liable linkage to G4.5 dendrimer. DOX is sensitive to light, 
temperature, ph and solvent used. DOX is more stable in acidic medium (pH 7.4 to pH 4.5) with 
maximum stability at pH 4. Although immense care was taken to conduct the experiment in dark, 
there was still some exposure to light, and higher pH of 7.4 led to photo-degradation of DOX 
after 192 hours, which turned it to a deep blue-purple compound. Due to this photo-degradation, 
the release kinetics studies were stopped at 192 hours. Huge standard deviation observed for pH 
4.5 at 192 hours can also be attributed to this photo-degradation. Statistical analysis showed 
significant difference between pH 4.5 vs. pH 5.5 and pH 4.5 vs. pH 7.4 (p<0.05), where as there 
was no significant statistical difference between pH 5.5 and pH 7.4. 
 
Figure 4.3 Cumulative release profiles of DOX from CTX-PEG-G4.5-DOX conjugates at 
different pH 
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4.6 Cytotoxicity studies  
HN12 cells were used to perform cytotoxicity tests. Untreated HN12 cells were used as a 
positive control.  The cells were incubated with DOX-G4.5-PEG-CTX or free DOX at DOX 
equivalent concentration of 100, 10 and 1 nmol (higher concentrations such as 1 and 10 µmol 
were highly cytotoxic with 0% cells viable after 24 hours). The amount of DOX-G4.5-PEG-CTX 
equivalent to free DOX also contained CTX at a concentration of 10, 1 and 0.1 nmol, thus cells 
were also incubated with equivalent free CTX concentration. The cytotoxicity was both dose and 
time dependent. As seen in Figure 4.4, DOX-G4.5-PEG-CTX conjugate was cytotoxic at all 
concentrations. A constant reduction in the activity of cells was indicated by Trypan blue test 
over a period of 72 hours (n=6), which indicated a controlled release of DOX from the 
nanoparticles which was also seen in the DOX release studies. There was no significant 
statistical difference within the groups over 72 hours except groups N1, D1, CTX1 and CTX0.1 
(p<0.05). When individual concentrations were compared, it was observed that the cytotoxicity 
of DOX-G4.5-PEG-CTX was much higher than that of the equivalent amount of free CTX. This 
increased cytotoxicity can be attributed to a combined effect of DOX and CTX as reported 
earlier (Vega et al., 2003; Liao et al., 2010). However, the cytotoxicity of DOX-G4.5-PEG-CTX 
was relatively less or equal to free DOX. This can be a result of the presence of biocompatible 
PEG in the dendrimer conjugates. Significant statistical difference was observed with all groups 
compared as whole with p<0.05. 
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Figure 4.4 Cytotoxicity studies of DOX-G4.5-PEG-CTX (N), free DOX (D) and free CTX at 
different equivalent concentration of DOX and CTX. (N100, N10, N1: DOX-G4.5-PEG-CTX at 
DOX equivalent concentration of 100, 10 and 1 nmol; D100, D10, D1: free DOX at 
concentration of 100, 10 and 1 nmol; CTX10, CTX1, CTX0.1: free cetuximab at DOX-G4.5-
PEG-CTX equivalent concentration of 10, 1 and 0.1 nmol) 
 
4.7 Cellular uptake studies 
Fluorescence microscopy was performed to investigate the mechanism behind free DOX and 
CTX-PEG-G4.5-DOX uptake in the HN12 cells. It was found that free DOX translocated from 
cytosol to the nucleus after 6 hours incubation as seen in Figure 4.5. It has been reported earlier 
that DOX penetrates the plasma and then diffuses into the nucleus, where it interacts with the 
DNA (Alton et al., 1998). On the other hand, after 6 hours of incubation, CTX-PEG-G4.5-DOX 
was present both in the cytosol and the nucleus. Cells internalize macromolecules via 
endocytosis. Endosomes have an acidic pH 6 due to the proton pump present on the membrane. 
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When these endosomes change from early endosomes to late endosomes, their internal pH goes 
further down to pH 5.5 (Cooper et al., 1977). The hydrazon linkage between the DOX and G4.5-
PEG-CTX should start breaking in the early and late endosomes stage inducing death signals in 
the cells (Rihova et al., 2002). Golgi apparatus releases transport vesicles which carry lysosomal 
hydrolases, which fuse with late endosomes to form lysosomes. The lysosomes are much more 
acidic with pH 4.5-pH 5 which would result in more release of DOX bound to the G4.5-PEG-
CTX conjugate and resulted in cell death as shown in cell viability. The cellular uptake results 
are similar to results found in earlier studies done with similar linkage of DOX with other 
polymers like HPMA (Etrych et al., 2002; Rihova et al., 2001), PEG (Rodrigues et al., 1999), 
and neuropeptide (Langer et al., 2001). The amount of free DOX and DOX-G4.5-PEG-CTX 
uptaken by the cells was found out using cell lysis studies. As seen in Figure 4.5 B and E, 
although equivalent concentrations of DOX were used still the intensity of DOX is much lower 
in cells treated with free DOX (Figure 4.5–B) to those treated with DOX-G4.5-PEG-CTX 
conjugates (Figure 4.5-E). It was found that after 6 hour incubation the uptake of DOX-G4.5-
PEG-CTX was ten-folds higher at 2.32 nmols/ µg of protein as compared to that of free DOX at 
0.25 nmols/ µg of protein, suggesting CTX facilitates particle uptake via receptor mediated 
endocytosis. 
4.8 Conclusion 
A tumor-targeted dendrimer-based delivery system carrying CNS drugs was synthesized 
through a 3-step layer-by-layer design mechanism. Chemotherapy drug doxorubicin was 
successfully conjugated to the dendrimer via acid-liable hydrazon linker. Monoclonal antibody 
cetuximab was successfully conjugated to the dendrimer via PEG linker as the targeting ligand. 
The conjugate was characterized with NMR, fluorescence anisotropy, UV-Vis, DLS, zeta 
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potential and Western blotting. A controlled release of DOX was observed at pH 4.5. The 
dendrimer conjugate was very stable at bloodstream pH of 7.4. Cytotoxicity of the dendrimer 
conjugate was considerably high compared to free cetuximab but was lower than free 
doxorubicin because of the addition of PEG chains.  
 
        
        
Figure 4.5 Cellular uptake of free DOX (A: Nucleus with DAPI, B: free DOX in nucleus, C: 
overlapped nucleus and free DOX) and DOX-G4.5-PEG-CTX (D: Nucleus with DAPI, E: DOX 
from DOX-G4.5-PEG-CTX, F: overlapped nucleus and DOX from DOX-G4.5-PEG-CTX) 
A B C 
D E F 
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CHAPTER 5 SUMMARY AND FUTURE WORK 
Synthetic polymers coupled with anticancer drugs can increase the efficacy and reduce the side-
effects of such drugs (Lai et al., 2007). Polymers can be easily modified as potent drug delivery 
systems. We designed a brain-targeted drug delivery system for high EGFR expressing tumors. 
We demonstrated the change in size and surface properties due to addition of functional moieties 
to dendrimers. Considering endocytic release of drug, we demonstrated pH sensitive drug release 
of doxorubicin; various other drugs can be incorporated in a similar way for future testing. 
Different protein assays can be used to characterize monoclonal antibody. All the studies done in 
this work were using cancer cells, further analysis can be done using in vitro BBB model. 
Further studies can be done to determine if the drug delivery system can be administered using 
an alternative drug administration route. BBB administration can be evaluated using only Fab’ 
fragments of the antibody as evaluated in an earlier work (Mamot et al., 2005). 
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Interpretation of the statistical analysis shown in Appendix A, B, C, D and E 
Analysis of Variance (ANOVA): 
 p < 0.05 indicates that the data is statistically significant 
Tukey’s Pairwise Comparisons: 
 Performed to determine statistical difference between two data values 
 Confidence interval (lower to upper) excludes zero : significant statistical difference 
between data values 
 Confidence interval (lower to upper) includes zero : insignificant statistical difference 
between data values 
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Appendix A (Statistical data for anisotropy) 
One Way Analysis of Variance (ANOVA): Anisotropy  
 
Data source: Data 1 in Notebook1 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.598) 
 
Equal Variance Test: Passed (P = 0.758) 
 
Group Name  N  Missing Mean Std Dev SEM  
r for DOX-G4.5-PEG 6 0 0.0538 0.00160 0.000654  
r for free DOX 6 0 0.0323 0.00137 0.000558  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 1 0.00139 0.00139 625.602 <0.001  
Residual 10 0.0000222 0.00000222    
Total 11 0.00141     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
 
Overall significance level = 0.05 
 
Comparisons for factor:  
 
Comparison Diff of Means t P P<0.050   
r for DOX-G4.5-PEG vs. r for free D 0.0215 25.012 <0.001 Yes   
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Appendix B (Statistical data for hydrodynamic size) 
One Way Analysis of Variance (ANOVA) : Particle size  
Data source: Data 1 in Notebook2 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook2 
Group N  Missing  Median    25%      75%     
G4.5 (nm) 10 0 3.529 2.780 3.615  
mal-PEG-G4.5 (nm) 10 0 5.606 5.523 5.828  
mal-PEG-G4.5-DOX (nm) 10 0 39.680 39.432 40.140  
H = 25.812 with 2 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q P<0.05   
mal-PEG-G4.5-DOX vs G4.5 (nm) 200.000 7.184 Yes   
mal-PEG-G4.5-DOX vs mal-PEG-G4.5  100.000 3.592 Yes   
mal-PEG-G4.5 (nm) vs G4.5 (nm) 100.000 3.592 Yes   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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Appendix C (Statistical data for zeta potential) 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook2 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook2 
 
Group N  Missing  Median    25%      75%     
G4.5 (mV) 10 0 -21.100 -21.225 -20.875  
mal-PEG-G4.5 (mV) 10 0 -18.650 -18.800 -17.275  
mal-PEG-G4.5-DOX (mV) 10 0 -2.595 -2.612 -2.543  
 
H = 25.864 with 2 degrees of freedom.  (P = <0.001) 
 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference  (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison Diff of Ranks q P<0.05   
mal-PEG-G4.5-DOX vs G4.5 (mV) 200.000 7.184 Yes   
mal-PEG-G4.5-DOX vs mal-PEG-G4.5  100.000 3.592 Yes   
mal-PEG-G4.5 (mV) vs G4.5 (mV) 100.000 3.592 Yes   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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Appendix D (Statistical data for cumulative release kinetics of DOX) 
One Way Analysis of Variance (ANOVA): Cumulative release kinetics of DOX 
Data source: Data 1 in Release kinetics.JNB 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
Data source: Data 1 in Release kinetics.JNB 
Group N  Missing  Median    25%      75%     
pH 7.5 12 0 15.350 13.500 18.300  
pH 5.5 12 0 19.600 14.225 29.400  
pH 4.5 12 0 40.227 33.815 53.149  
H = 22.677 with 2 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q P<0.05   
pH 4.5 vs pH 7.5 237.500 6.507 Yes   
pH 4.5 vs pH 5.5 173.500 4.754 Yes   
pH 5.5 vs pH 7.5 64.000 1.754 No   
Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Appendix E (Statistical data for cytotoxicity assay) 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook3 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook3 
 
Group N  Missing  Median    25%      75%    
N100 9 0 131000.000 106000.000 175500.000  
N10 9 0 260000.000 204000.000 325000.000  
N1 9 0 229000.000 204000.000 436500.000  
D100 9 0 173000.000 143000.000 219500.000  
D10 9 0 169000.000 133500.000 270500.000  
D1 9 0 208000.000 129500.000 307500.000  
CTX10 9 0 309000.000 220000.000 429500.000  
CTX1 9 0 347000.000 253500.000 415500.000  
CTX0.1 9 0 329000.000 247500.000 485500.000  
 
H = 30.710 with 8 degrees of freedom.  (P = <0.001) 
 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference  (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison Diff of Ranks q P<0.05   
CTX0.1 vs N100 406.000 5.752 Yes   
CTX0.1 vs D10 286.500 4.059 No   
CTX0.1 vs D100 286.000 4.052 Do Not Test   
CTX0.1 vs D1 218.500 3.096 Do Not Test   
CTX0.1 vs N10 140.500 1.991 Do Not Test   
CTX0.1 vs N1 109.000 1.544 Do Not Test   
CTX0.1 vs CTX10 52.500 0.744 Do Not Test   
CTX0.1 vs CTX1 26.500 0.375 Do Not Test   
CTX1 vs N100 379.500 5.377 Yes   
CTX1 vs D10 260.000 3.684 Do Not Test   
CTX1 vs D100 259.500 3.677 Do Not Test   
CTX1 vs D1 192.000 2.720 Do Not Test   
CTX1 vs N10 114.000 1.615 Do Not Test   
CTX1 vs N1 82.500 1.169 Do Not Test   
CTX1 vs CTX10 26.000 0.368 Do Not Test   
CTX10 vs N100 353.500 5.009 Yes   
CTX10 vs D10 234.000 3.315 Do Not Test   
CTX10 vs D100 233.500 3.308 Do Not Test   
CTX10 vs D1 166.000 2.352 Do Not Test   
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CTX10 vs N10 88.000 1.247 Do Not Test   
CTX10 vs N1 56.500 0.801 Do Not Test   
N1 vs N100 297.000 4.208 No   
N1 vs D10 177.500 2.515 Do Not Test   
N1 vs D100 177.000 2.508 Do Not Test   
N1 vs D1 109.500 1.551 Do Not Test   
N1 vs N10 31.500 0.446 Do Not Test   
N10 vs N100 265.500 3.762 Do Not Test   
N10 vs D10 146.000 2.069 Do Not Test   
N10 vs D100 145.500 2.061 Do Not Test   
N10 vs D1 78.000 1.105 Do Not Test   
D1 vs N100 187.500 2.657 Do Not Test   
D1 vs D10 68.000 0.963 Do Not Test   
D1 vs D100 67.500 0.956 Do Not Test   
D100 vs N100 120.000 1.700 Do Not Test   
D100 vs D10 0.500 0.00708 Do Not Test   
D10 vs N100 119.500 1.693 Do Not Test   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums  4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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Appendix F (Properties and handling of DOX) 
General Details 
Approved name: Doxorubicin, Doxorubicin Hydrochloride 
Derivation: Strptomyces peucetius var. caesius 
Proprietary name: Adriamycin 
Diseases: Hematological malignancies, Carcinoma, Soft tissue sarcomas, Metastatic endometrial 
cancer and advanced ovarian cancer 
Dissolution:  Sterile, pyrogen-free, orange-red, freeze dried powder 
Storage and shelf life: 
 Light Sensitive 
 Dry, unopened: Dry place away from light, Three years  
 Solution: 2 to 8 ˚C, Eighteen months 
 Removed from refrigeration: One Month 
 
Chemistry 
Type: Cytotoxic antibody containing 
 An  aminosugar, daunosamine  
 Gylcosidic bond to C7  
 Tetracyclic aglycone, doxorubicinone 
Action 
 Complex with DNA 
 Interferes nucleic acid synthesis  
 Highest activity : S phase   
 
Molecular Study 
Molecular structure  
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Molecular Weight: 580.0 
 
Solubility  
 Water 
 5% Glucose 
 0.9% Sodium Chloride 
 Partially in Alcohol 
Insoluble 
 Chloroform, ether, other organic solvents 
 
Stability Profile 
Physical and chemical stability 
 48 hours at room temperature in normal artificial light 
 18 months at 2-8˚C at pH 3.0 
 One month at room temperature at pH 3.0 
Stability depends 
 Temperature 
 pH 
 Solvent 
Light sensitive 
Absorbs on to glass and certain plastics 
 
Effect of pH 
More stable in acidic medium (pH 7.4 to pH 4.5) 
 Maximum at pH 4.0 
Below pH 4.0 
 Acidic hydrolysis – red-colored, water insoluble aglycone and water-soluble amino sugar 
 Rate proportional to hydrogen ion concentration 
 Aglycone is inactive 
 Dependent on structural modification in amino sugar 
Above pH 4.0 
 Color change from red to deep blue-purple 
 Rapid degradation occurs 
 At pH 8.0, fluorescing compounds 
pH ≤ 9.5 
 Accelerated by acetate, phosphate and carbonate buffers 
pH > 10.0 
 No buffer catalysis 
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Alkaline solution 
 Anthracyclines are affected by structural modification of aglycone portion of the 
molecule 
 
Photodegradation 
Substantial photodegradation observed at concentrations below 100 µg/ml.  
No special precautions are needed at Concentrations ≥ 500 µg/ml  
 
Effect of Temperature 
Stability  
 Water, concentration 2 mg/ml, 4˚C polypropylene syringe, 6 months 
 25 ˚C in dark 
o 5% glucose, pH 4.7 
o 3.3% glucose with 0.3% sodium chloride, pH 4.4 
o Polypropylene tubes for 28 days 
o Significant degradation in six days in 0.9% sodium chloride, pH 7.0 
 PVC minibags 
o 0.9% sodium chloride, pH 6.7 at 25 ˚C in dark 
o Loss in potency 
o 5% glucose, pH 4.36 and 0.9% sodium chloride (pH 5.2 and pH 6.47), 43 days at 
4˚C 
 Freezing Doxorubicin 
o 2 mg/ml aqueous solution, one month, -20 ˚C 
o Cannot be frozen with sodium chloride 
o 5% glucose, pH 4.36 and 0.9% sodium chloride (pH 5.2 and pH 6.47), 43 days at 
-20˚C 
 Microwave Radiation 
o Concentration reduces after four re-thawing  in microwave 
o Stable for 2 weeks thawed by any means 
o Aqueous solutions frozen and thawed seven times 
o Overheating may lead to degradation 
o Thawing in microwave NOT RECOMMENDED 
 
Container Compatibility 
Polypropylene, polyethylene, PVC and glass 
More stable in plastics than glass 
Absorbs on to glass and polyethylene 
Diluted solutions absorb more on membranes 
Negligible absorbance at concentrations of at least 500 µg/ml 
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Compatibility with other drugs 
Incompatible 
 Heparin, dexamethasome sodium phosphate, hydrocortisone sodium succinate and 
diazepam 
 Combination with fluorouracil or aminophylline resuls in color change 
Compatible in  
 Vincristine, but with buffer 
 Recommended NOT to be mixed with any drug 
 
Destruction 
Incineration – 700 ˚C 
Chemical 
 Dilute sodium hypochlorite for 24 hours 
Contact with skin 
 Wash with water, soap or sodium bicarbonate solution 
Contact with eyes 
 Irrigation with saline 
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Appendix G (Gravity protocol of PD-10 column) 
(Based on GE Healthcare, Instructions 52-1308-00 BB) 
PD-10 properties 
 Sephadex
TM
 G-25 medium 
 Uses: Desalting, buffer exchange and removal of low-molecular weight impurities 
 Particle size range: 85-260 µm 
 Bed dimention: 1.45 x 5.0 cm, 8.3 ml 
 Exclusion limit: 5000 
 Chemical stability: All common buffers 
 Working pH: 2-13 
 Storage temperature: +4 to +30˚C 
 Storage solution: 0.15% Kathon CG/ICP Biocide 
Protocols  
 Gravity protocol 
 Spin protocol 
Properties Gravity protocol Spin protocol 
Description Use of Gravity force 
Higher recovery 
Applied sample is diluted 
Additional force by spinning 
in centrifuge 
No dilution of sample 
Sample volume 1.0-2.5 ml 1.75-2.5 ml 
Elution buffer 3.5 ml None 
Dilution factor 1.4 times None 
Desalting capacity >98% >90% 
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Gravity protocol 
1. Remove the top cap and discard the column storage solution 
2. Cut the seal at the end of column using scissors 
3. Fix the column secure on burette stand 
4. Take 25 ml of equilibration buffer equilibrate column up to four times 
a. Fill column with buffer and let the bed be completely soaked. 
b. Discard the flow-through buffer 
5. Add 2.5 ml of sample 
a. If sample is lesser than 2.5, after the sample is completely soaked in column, add 
equilibration buffer to adjust the volume to 2.5 ml 
b. Discard the flow through 
6. Use 3.5 ml of buffer to elute samples 
7. Place microcentrifuge tubes below the column to collect samples at fixed time intervals 
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